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To the Editor:
In their prospective observational cohort
study, Micek et al. investigated 137 patients
with septic shock treated with norepinephrine
(NE) with or without vasopressin [1]. In a mul-
tivariate subgroup analysis, the authors found
additional vasopressin administration to be the
most significant independent risk factor for 
the 28-day mortality rate. The authors also re-
ported that vasopressin administration itself is
associated with a higher mortality rate than NE
alone.
Because of the study design (observational,
not randomized), the results are appropriate
only to generate a hypothesis that has to be
tested in a randomized, controlled trial. The re-
sults of such a trial (Vasopressin and Septic
Shock Trial; VASST) suggest that there is no
significant difference in the overall mortality
rate in patients treated with either NE alone or
the combination of NE and low-dose vaso-
pressin (max. 0.03 U/min) [2]. However, a pre-
defined a priori analysis provided evidence
that among the subpopulation with less severe
sepsis (NE dose  15 mcg/min), vasopressin
infusion was associated with a significantly re-
duced 28- and 90-day mortality rate. In view of
these results, vasopressin infusion in septic
shock in doses not exceeding 0.03 U/min has
to be regarded as a safe treatment option.
Notably, patient characteristics and process-
of-care variables revealed statistically signifi-
cant differences between the two subgroups. In
this context, it is noteworthy that patients
treated with vasopressin had higher body mass
indices and more acquired organ failures, as
well as a greater necessity for mechanical ven-
tilation and treatment with drotrecogin alfa
activated than the patients treated with NE
only. In addition, there was a tendency toward
higher Acute Physiology and Chronic Health
Evaluation (APACHE) II scores in the vaso-
pressin group. Therefore, it is not surprising
that the mortality rate was higher in the more
severely ill subgroup.
Although the authors emphasized that vaso-
pressin was administered early in the treatment
algorithm, there was a great difference between
the median (8 h) and mean (27.5  52.8 h) du-
ration of NE infusion prior to vasopressin ad-
ministration, suggesting that the variables were
not normally distributed. It therefore appears
that vasopressin was used as a “last resort ther-
apy” in a considerable number of patients. This
assumption is supported by the fact that indi-
vidual physicians had no definite protocol for
the addition of vasopressin.
In summary, Micek et al. have not demon-
strated that adding low-dose vasopressin to NE
infusion increases the mortality rate of patients
with septic shock. Future studies are needed to
confirm the notion that low-dose vasopressin,
when given in the early stage of sepsis, may ac-
tually improve survival.
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LETTER TO THE EDITOR
To the Editor:
I thank Doctors Rehberg et al. for their in-
terest in our paper. I agree with their impor-
tant point that the findings of this study are hy-
pothesis-generating as a result of the study
design. Nonetheless, we believe many impor-
tant points regarding vasopressin plus norepi-
nephrine infusion for septic shock can be de-
rived from this study.
First, the primary analysis focused on differ-
ences in processes of care between surviv-
ors and non-survivors. As expected, impor-
tant differences in baseline characteristics and
process-of-care variables were found in the two
groups. To control for this potential variance,
multivariable regression analysis was per-
formed, which revealed four significant predic-
tors of the 28-day mortality rate: Inappropriate
initial antimicrobial therapy, lack of goal-
directed volume resuscitation, increasing
APACHE II score, and the administration of va-
sopressin in combination with norepinephrine.
Second, a comparison between the two va-
sopressor regimens was conducted. Whereas
the severity of illness in the groups clearly was
different, optimal bipartite graph matching
was utilized to match patients receiving nor-
epinephrine alone with the most similar pa-
tients receiving norepinephrine plus vaso-
pressin. In the graph-matched patients, the
administration of vasopressin plus norepi-
nephrine was associated with a significantly
higher 28-day mortality rate than vasopressor
support with norepinephrine alone. These two
modalities of controlling for confounding vari-
ables increase our confidence that vasopressin
may not be a safe therapy.
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